MDT

85.33

-3.72%↓

VEEV

216.41

-0.82%↓

A

105.19

-5.12%↓

HQY

78.99

-5.63%↓

PDCO

31.09

-0.54%↓

MDT

85.33

-3.72%↓

VEEV

216.41

-0.82%↓

A

105.19

-5.12%↓

HQY

78.99

-5.63%↓

PDCO

31.09

-0.54%↓

MDT

85.33

-3.72%↓

VEEV

216.41

-0.82%↓

A

105.19

-5.12%↓

HQY

78.99

-5.63%↓

PDCO

31.09

-0.54%↓

MDT

85.33

-3.72%↓

VEEV

216.41

-0.82%↓

A

105.19

-5.12%↓

HQY

78.99

-5.63%↓

PDCO

31.09

-0.54%↓

MDT

85.33

-3.72%↓

VEEV

216.41

-0.82%↓

A

105.19

-5.12%↓

HQY

78.99

-5.63%↓

PDCO

31.09

-0.54%↓

Search

Abbott Laboratories

Aperta

SettoreSettore sanitario

128.98 -3.08

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

128.69

Massimo

132.57

Metriche Chiave

By Trading Economics

Entrata

7.6B

9.2B

Vendite

339M

11B

P/E

Media del settore

17.363

63.778

EPS

1.34

Rendimento da dividendi

1.78

Margine di Profitto

84.099

Dipendenti

114,000

EBITDA

82M

3B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+6.52% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.78%

2.39%

Utili prossimi

16 apr 2025

Prossima data del Dividendo

15 mag 2025

Prossima data del' Ex Dividendo

15 apr 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.8B

230B

Apertura precedente

132.06

Chiusura precedente

128.98

Notizie sul Sentiment di mercato

By Acuity

33%

67%

94 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Abbott Laboratories Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2025, 19:03 UTC

Utili

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 gen 2025, 18:20 UTC

Utili

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 gen 2025, 12:45 UTC

Utili

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

1 nov 2024, 14:15 UTC

I principali Market Mover

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

1 nov 2024, 10:10 UTC

I principali Market Mover

Reckitt Shares Surge After Baby Formula Lawsuit Win

31 ott 2024, 23:57 UTC

Azioni calde

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31 ott 2024, 23:14 UTC

I principali Market Mover

Abbott Laboratories Shares Rise After Baby-Formula Verdict

16 ott 2024, 12:03 UTC

Utili

Abbott Laboratories 3Q Sales Top Expectations

1 feb 2025, 18:14 UTC

Notizie principali

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 gen 2025, 16:40 UTC

Notizie principali
Utili

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 gen 2025, 15:20 UTC

Utili

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 gen 2025, 15:08 UTC

Utili

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 gen 2025, 13:51 UTC

Utili

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 gen 2025, 13:39 UTC

Notizie principali
Utili

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 gen 2025, 12:02 UTC

Utili

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 gen 2025, 12:01 UTC

Utili

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 gen 2025, 12:01 UTC

Utili

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q Net $9.23B >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q Sales $10.97B >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q EPS $5.27 >ABT

22 gen 2025, 12:00 UTC

Utili

Abbott Labs 4Q Adj EPS $1.34 >ABT

22 gen 2025, 09:54 UTC

Azioni calde

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

1 nov 2024, 17:33 UTC

Discorsi di Mercato

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

16 ott 2024, 14:21 UTC

Notizie principali
Utili

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

16 ott 2024, 12:25 UTC

Utili

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

16 ott 2024, 12:02 UTC

Notizie principali
Utili

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

16 ott 2024, 11:59 UTC

Utili

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

16 ott 2024, 11:37 UTC

Utili

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Confronto tra pari

Modifica del prezzo

Abbott Laboratories Previsione

Obiettivo di Prezzo

By TipRanks

6.52% in crescita

Previsioni per 12 mesi

Media 140.21 USD  6.52%

Alto 158 USD

Basso 117 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Abbott Laboratories - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

14

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

126.38 / 131.69Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

94 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.